ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy

Dosso, Sara De; Zanellato, Elena; Nucifora, Martina; Boldorini, Renzo; Sonzogni, Angelica; Biffi, R.; Fazio, Nicola; Bucci, E; Beretta, Ottavio; Crippa, Stefano; Saletti, Piercarlo; Frattini, Milo

doi:10.1007/s00280-013-2181-2

Cited by 39 publications

(34 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In patients with surgically resected NSCLC who do not receive adjuvant chemotherapy, those with high ERCC1 expression experience longer survival than patients with low ERCC1 expression [133] Preclinical data evaluating the predictive and prognostic value of ERCC1 in GC has revealed mixed results. Similar to in NSCLC, ERCC1 has been found to be a negative predictive factor in a European population receiving adjuvant cisplatin-based chemotherapy after gastrectomy because ERCC1 negativity was associated with longer OS [134]. Similar results were seen in an Asian population that received adjuvant oxaliplatinbased chemotherapy [135].…”

Section: Potential New Targetssupporting

confidence: 71%

How Prognostic and Predictive Biomarkers Are Transforming Our Understanding and Management of Advanced Gastric Cancer

2014

View full text Add to dashboard Cite

Background. Gastric cancer (GC) is the second leading cause of cancer death worldwide. GC is a heterogeneous disease in terms of histology, anatomy, and epidemiology. There is also wide variability in how GC is treated in both the resectable and unresectable settings. Identification of prognostic and predictive biomarkers is critical to help direct and tailor therapy for this deadly disease. Methods. A literature search was done using Medline and MeSH terms for GC and predictive biomarkers and prognostic biomarkers. The search was limited to human subjects and the English language. There was no limit on dates. Published data andunpublishedabstracts with clinicalrelevance were included. Results. Many potential prognostic and predictive biomarkers have been assessed for GC, some of which are becoming practice changing. This review is focused on clinically relevant

show abstract

Section: Potential New Targetssupporting

confidence: 71%

How Prognostic and Predictive Biomarkers Are Transforming Our Understanding and Management of Advanced Gastric Cancer

2014

View full text Add to dashboard Cite

show abstract

“…Significantly longer OS (P = 0.04) was found in patients categorized as ERCC1 negative by immunohistochemistry. Thus, ERCC1 may help in predicting which patients are more likely to benefit from adjuvant cisplatin-based chemotherapy in curatively resected gastric cancer (De Dosso et al, 2013). In a study from China, the effects of ERCC1 expression on survival in were evaluated in 57 gastric cancer patients treated with surgery followed by oxaliplatin-based adjuvant chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

“…High tumoral expression of ERCC1 was associated with decreased OS in patients who received platinum-based adjuvant chemotherapy (16.7 months vs 53.8 months; P = 0.03) (Squires et al, 2013). In the investigation by De Dosso et al (2013), the expression of ERCC1 expression in tumor samples obtained from surgical specimens of 68 patients treated with adjuvant cisplatin-based chemotherapy for gastric cancer were analyzed by immunohistochemistry. Significantly longer OS (P = 0.04) was found in patients categorized as ERCC1 negative by immunohistochemistry.…”

Section: Discussionmentioning

confidence: 99%

Correlation of ERCC1 expression in peripheral blood lymphocytes with outcomes of patients with gastric cancer treated with oxaliplatin-based adjuvant chemotherapy

Zhang

Wang

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. Excision repair cross-complementing gene-1 (ERCC1) is a key regulatory enzyme whose expression patterns in tumor tissues are associated with survival in gastric cancer. The present study aimed to evaluate the effects of ERCC1 expression in peripheral blood lymphocytes (PBLs) on the outcome of patients with gastric cancer treated with oxaliplatin-based adjuvant chemotherapy. Tumor and PBL samples from 48 patients treated with adjuvant oxaliplatin-based chemotherapy for gastric cancer were analyzed. Immunohistochemistry was used to assess the expression of ERCC1. After a median follow-up of 18.5 months, the median disease-free survival (DFS) and overall survival (OS) were 12 and 20 months, respectively. Expression of ERCC1 was found in 72.9% (35/48), 56.3% (27/48), and 10.0% (2/20) of tumor tissues, PBLs from gastric cancer patients, and PBLs from controls, respectively. A significant 15921-15929 (2015) positive correlation between ERCC1 expression in PBL and cancer tissue was found (χ 2 = 12.098, P = 0.001, Pearson contingency coefficient = 0.502). Patients with negative expression of ERCC1 in tumor tissues had a significantly longer median DFS and median OS compared to patients with positive expression of ERCC1 (median DFS, 18 vs 10 months, P = 0.006; median OS, 30 vs 17 months, P = 0.012). In PBLs, high expression of ERCC1 was associated with decreased DFS (9 vs 18 months, P = 0.032), but not OS (16 vs 24 months, P = 0.057). Patients with gastric cancer exhibiting negative expression of ERCC1 are more likely to benefit from oxaliplatin-based adjuvant chemotherapy.

show abstract

“…Excision repair cross-complementation group 1 (ERCC1) is an endonuclease essential in the nucleotide excision repair pathway and plays a role in DNA repair capacity and cancer risk as well as the clinical outcome of cancer (Wang et al, 2005). Recently, several studies suggested that variants in ERCC1 influence the susceptibility to and prognosis of various cancers Mlak et al, 2013;Yang et al, 2013;De Dosso et al, 2013). Few studies have investigated the role of ERCC1 variants in the clinical outcome in NSCLC (Ozdemir et al, 2013;Mlak et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

Effect of ERCC1 polymorphism on the response to chemotherapy and clinical outcome of non-small cell lung cancer

Gao¹,

Ge²,

Liu³

et al. 2014

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. We conducted a cohort study to investigate the role of 3 single-nucleotide polymorphisms of the excision repair crosscomplementation group 1 (ERCC1) gene on the response to chemotherapy and clinical outcomes of non-small cell lung cancer (NSCLC). A total of 163 patients with newly diagnosed and histopathologically confirmed primary NSCLC were examined in our study and were followed up until December 2012. ERCC1 rs11615, rs3212986, and rs2298881 were selected and genotyped. Of the 163 patients, 86 patients showed a complete response and partial response to chemotherapy (52.76%), while 91 patients (55.83%) died from NSCLC during the follow-up period with a median survival time of 19.3 months (range, 2-60 months). Multivariate regression analysis showed that individuals carrying the rs11615 TT genotype and T allele had a significantly lower response rate to chemotherapy using the rs11615 CC genotype as the reference. For rs3212986, carriers of the rs3212986 AA genotype and A allele had a significantly lower response rate to chemotherapy when compared with the CC genotype. In the Cox proportional hazards model, patients carrying the rs11615 TT genotype and T allele and the rs3212986 AA genotype and A allele were significantly associated with increased risk of death from NSCLC. We found that polymorphisms in ERCC1 rs11615 and rs3212986 were associated with poor response to chemotherapy and shorter survival time of advanced NSCLC.

show abstract

ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy

Abstract: Excision repair cross-complementing gene 1 by IHC might predict patients more likely to benefit from adjuvant cisplatin-based chemotherapy in curatively resected gastric cancer. In patients exhibiting ERCC1 positive tumors, alternative regimens should be evaluated.

Cited by 39 publications

References 36 publications

How Prognostic and Predictive Biomarkers Are Transforming Our Understanding and Management of Advanced Gastric Cancer

How Prognostic and Predictive Biomarkers Are Transforming Our Understanding and Management of Advanced Gastric Cancer

Correlation of ERCC1 expression in peripheral blood lymphocytes with outcomes of patients with gastric cancer treated with oxaliplatin-based adjuvant chemotherapy

Effect of ERCC1 polymorphism on the response to chemotherapy and clinical outcome of non-small cell lung cancer

Contact Info

Product

Resources

About